Related Experiment Video
Updated: Dec 12, 2025
08:38
Targeted DNA Methylation Analysis by Next-generation Sequencing
Published on: February 24, 2015
37.8K
DNA CpG methylation in sequential glioblastoma specimens.
Zoltan Kraboth1,2, Bence Galik2,3, Marton Tompa1,2
1Institute of Laboratory Medicine, School of Medicine, University of Pecs, Pecs, Hungary.
Journal of Cancer Research and Clinical Oncology
|August 12, 2020
Summary
Analyzing DNA methylation in glioblastoma (GBM) reveals molecular changes driving tumor growth and recurrence. Identifying these epigenetic alterations offers potential new therapeutic targets for this aggressive brain cancer.
Area of Science:
- Neuro-oncology
- Epigenetics
- Molecular Biology
Background:
- Glioblastoma (GBM) is a highly aggressive brain tumor with limited treatment options.
- Understanding the molecular drivers of GBM evolution is crucial for developing effective therapies.
- Epigenetic modifications, like DNA methylation, play a significant role in cancer development.
Purpose of the Study:
- To identify molecular drivers of glioblastoma development and recurrence.
- To analyze DNA CpG methylation patterns in sequential primary and recurrent GBM samples.
- To uncover potential therapeutic targets based on epigenetic alterations.
Main Methods:
- DNA was extracted from 22 pairs of primary and recurrent GBM specimens.
- Reduced representation bisulfite sequencing was employed to analyze DNA methylation.
- Bioinformatic and biostatistical analyses identified differentially methylated pathways and correlated them with clinical parameters.
Main Results:
- Primary GBM development was associated with differential methylation in neuronal differentiation, myelination, metabolic processes, and angiogenesis pathways.
- Glioblastoma recurrence involved altered methylation in cell processes, immune response, Wnt regulation, and catecholamine secretion/transport pathways.
- Hypomethylation was observed in neuronal tissue development and angiogenesis during early tumor growth.
Conclusions:
- DNA CpG methylation analysis in sequential GBM samples highlights key pathways involved in tumor progression and recurrence.
- Altered regulation of catecholamine secretion, Wnt signaling, and immune response pathways are implicated in GBM recurrence.
- Identified epigenetic alterations in neuronal development, angiogenesis, and other pathways represent promising avenues for novel therapeutic strategies.
